Source comparison
BPC-157 TB-500 for ACL Recovery: Comparison Table
Primary Mechanism VEGF upregulation, NO pathway modulation, angiogenesis Actin binding, cell migration, fibroblast recruitment Synergistic vascularization + cellular migration Stack addresses multiple rate-limiting steps Typical Dosing 200–500 mcg/day subcutan
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF upregulation, NO pathway modulation, angiogenesis
- Actin binding, cell migration, fibroblast recruitment
- Synergistic vascularization + cellular migration
- Stack addresses multiple rate-limiting steps
- Typical Dosing
- 200–500 mcg/day subcutaneous near injury site
- 2–10 mg/week split into 2 doses during loading phase
- Both run concurrently or staggered by healing phase
- Concurrent use most common in athletic recovery
- Onset of Effect
- 7–14 days (early angiogenesis markers visible)
- 10–21 days (tissue remodeling begins)
- Overlapping effects starting week 2
- Earlier functional improvement with stack
- Evidence Base
- Rat ligament models, case reports, no RCTs in humans
- Equine tendon studies, limited human data
- No controlled trials on combination therapy
- Mechanistic rationale strong, clinical proof incomplete
- Regulatory Status
- Not FDA-approved for human use; research peptide only
- Both compounds sold for research purposes under FDA oversight
- Legal only when sourced from licensed research suppliers
- Cost (4-week cycle)
- Approximately $80–$150 depending on supplier and purity
- Approximately $200–$350 for loading phase supply
- Combined cost $280–$500 per month
- Significantly cheaper than biologics like PRP or stem cells